F Piccinino

Effect of Long-term Propranolol Treatment on Hepatocellular Carcinoma Incidence in Patients with HCV-Associated Cirrhosis

Memory CD8 + T Cells Are Required for Protection from Persistent Hepatitis C Virus Infection

The natural course of HCV infection and the need for treatment

Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal study

Cancer statistics, 2018

Infection with GB Virus C and Reduced Mortality among HIV-Infected Patients

Hepatocellular carcinoma

Natural history of hepatitis B

Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis

A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study1 1The other PROACTIVE Study Group investigators included the following: Vijayan Balan, M.D., Mayo Clinic Scottsdale, Scottsdale, Arizona; Norbert Bräu, M.D., Bronx VA Medical Center, Bronx, New York; Robert Brown, M.D., M.P.H., NY Presbyterian Medical Center, New York, New York; William Carey, M.D., Cleveland Clinic Foundation, Cleveland, Ohio; Andrea Duchini, M.D., Baylor College of Medicine, Houston, Texas; Greg Everson, M.D., University of Colorado Health Sciences Center, Denver, Colorado; Michael Fried, M.D., University of North Carolina, Chapel Hill, North Carolina; Robert Gish, M.D., California Pacific Medical Center, San Francisco, California; Ira Jacobson, M.D., Weill Medical College of Cornell University, New York, New York; John W. King, LSU Health Sciences Center, Shreveport, LA; Raymond Koff, M.D., University of Massachusetts Memorial Health Care, Worcester, Massachusetts; William Lee, M.D., University of Texas Southwestern Medical Center, Dallas, Texas; Mark A. Levstik, M.D., The University of Tennessee, Memphis, Tennessee; John G. McHutchison, M.D., Scripps Clinic, La Jolla, California; Marion Peters, M.D., University of California San Francisco, San Francisco, California; Kenneth Sherman, M.D., Ph.D., University of Cincinnati College of Medicine, Cincinnati, Ohio; Coleman Smith, M.D., Minnesota Clinical Research Center, St. Paul, MN; Ronald Wasserman, M.D., Hepatitis Resource Center, Walnut Creek, California.

Hepatocellular carcinoma

Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma

Hepatitis C Virus Infection

Rising Incidence of Hepatocellular Carcinoma in the United States

Reducing the neglected burden of viral hepatitis in Africa: Strategies for a global approach

Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

Architects of assembly: roles of Flaviviridae non-structural proteins in virion morphogenesis

Hepatocellular carcinoma

The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994

A Humanized Mouse Model to Study Hepatitis C Virus Infection, Immune Response, and Liver Disease

Hepatitis B virus infection

Impracticability of Informed Consent in the Registry of the Canadian Stroke Network

Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy

Epoetin Alfa Improves Quality of Life in Anemic Hcv–Infected Patients Receiving Combination Therapy

Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease

Diagnosis, management, and treatment of hepatitis C: An update # † ‡

Massive APOBEC3 Editing of Hepatitis B Viral DNA in Cirrhosis

Epidemiology of hepatitis C

Management of Hepatocellular Carcinoma *

Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression

Liver-Derived Hepatitis C Virus (HCV)-Specific CD4+ T Cells Recognize Multiple HCV Epitopes and Produce Interferon Gamma

Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection.

Epidemiology of hepatitis C

Mechanisms of Hepatic Fibrogenesis

Treating hepatitis C

Analysis of a Successful Immune Response against Hepatitis C Virus

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

Sustained virological response to interferon plus ribavirin reduces liver‐related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus†

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

Occult hepatitis B virus infection

Inhibition of hepatitis C virus p7 membrane channels in a liposome-based assay system

Interferons α and λ Inhibit Hepatitis C Virus Replication With Distinct Signal Transduction and Gene Regulation Kinetics

Persistent Hepatitis B Virus Infection in Subjects Without Hepatitis B Surface Antigen: Clinically Significant or Purely “Occult”?

Repertoires of Autophagy in the Pathogenesis of Ocular Diseases

Occult hepatitis B

Understanding the hepatitis C virus life cycle paves the way for highly effective therapies

Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis

Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

Hepatocellular Carcinoma

Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus–Related Cirrhosis

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

The way forward in HCV treatment — finding the right path

Parvovirus B19

Outcome of Sustained Virological Responders With Histologically Advanced Chronic Hepatitis C†,‡,§,¶

Treatment of HCV Infection by Targeting MicroRNA

Replication of hepatitis C virus

A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides p24 delta and p27 delta

Hepatocellular Carcinoma

Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma

Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy

Survival in Chronic Hepatitis B

Natural History of Chronic Hepatitis B Virus Infection in Taiwan: Studies of Hepatitis B Virus Dna in Serum

Telaprevir for Previously Treated Chronic HCV Infection

Variability of hepatitis C virus

Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: properties of the NS5A-associated kinase

Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C

TREATMENT OF CHRONIC HEPATITIS DUE TO HEPATITIS B VIRUS

Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C

Studying Hepatitis C Virus: Making the Best of a Bad Virus

Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection

Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis

Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype

Fibrosis — A Common Pathway to Organ Injury and Failure

Amino Acid Variations in Hepatitis C Virus P7 and Sensitivity to Antiviral Combination Therapy with Amantadine in Chronic Hepatitis C

A human parvovirus-like virus inhibits haematopoietic colony formation in vitro

Transcriptional Activation of the Interleukin-2 Promoter by Hepatitis C Virus Core Protein

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

RNA editing of hepatitis B virus transcripts by activation-induced cytidine deaminase

Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response

Accumulation of B Lymphocytes with a Naive, Resting Phenotype in a Subset of Hepatitis C Patients

Lack of Phenotypic and Functional Impairment in Dendritic Cells from Chimpanzees Chronically Infected with Hepatitis C Virus

Delta hepatitis — Present status

Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis

Erythrocyte P Antigen: Cellular Receptor for B19 Parvovirus

Haematological Changes in Viral (MHV-3) Murine Hepatitis

Isolated anti‐HBc in chronic hepatitis C predicts a poor response to interferon treatment

Interferon‐α plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study

Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: A retrospective study

Liver histology in patients with HBsAg negative anti‐HBc and anti‐HCV positive chronic hepatitis

Non responders to interferon therapy among chronic hepatitis patients infected with hepatitis C virus

CV genotype and “silent” HBV coinfection: Two main risk factors for a more severe liver disease

Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in ‘real world’ patients with chronic hepatitis C

Virologic and Clinical Expressions of Reciprocal Inhibitory Effect of Hepatitis B, C, and Delta Viruses in Patients With Chronic Hepatitis

Influence of Chronic Coinfection with Hepatitis B and C Virus on Liver Histology

Hepatitis C virus infection in households of anti-HCV chronic carriers in Italy: A multicentre case-control study

Effect of Immunosuppressive Therapy on HBsAg-Positive Chronic Active Hepatitis in Relation to Presence or Absence of HBeAg and Anti-HBe

Familiar clustering and spreading of hepatitis delta virus infection

SERUM LEVELS OF HEPATITIS B SURFACE AND CORE ANTIGENS DURING IMMUNOSUPPRESSIVE TREATMENT OF HBsAg-POSITIVE CHRONIC ACTIVE HEPATITIS